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Introduction: Familial amyloid polyneuropathy (FAP) is an autosomic
dominant disease due to the mutation in the transthyretin gene. The abnormal
protein produced by the liver is responsible for polyneuropathy, autonomic
dysfunction and cardiac involvement. Myocardial hypertrophy and conduction
disturbances are the two major cardiac consequences in FAP. More than 100
mutations have been described: the substitution of methionine for valine at
position 30 (Val30Met mutation) is the most common.
Methods: The aim of our study was to compare cardiac data of the Val30Met
population to other FAP population. One hundred ninety four consecutive patients
(pts) were referred to our department to have a cardiac evaluation after FAP diag-
nosis,168 pts out of them were genotyped. Standard ECG, echocardiography and
electrophysiological study were performed for each patient.
Results: Main results are shown in table 1. In patients carrying other muta-
tions than Val30Met, cardiac hypertrophy was associated with a longer HV
interval (71±2ms in case of hypertrophy vs. 58±4ms ;P=0.0008). Such associ-
ation wasn’t found considering Val30Met patients.
Table 1: Main results
Abnormal ECG: RBB, LBB, abnormal axis or nodal AV block. Cardiac
hypertrophy: interventricular septum thickness >12 mm. LW: lucianni Wenck-
ebach anterior point.
Conclusions: Demographic data and cardiac phenotype are significantly
different according to the genotype between the val30met and other mutations
population. In pts carrying other mutation than Val30Met, cardiac hypertrophy
and infra nodal block were more common and seemed to be related. Follow
up and treatment must take into a count the genotype. 
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Background: Ephrin-B1 is a ligand from Eph/Ephrin family involved in
cell-cell interactions. If the role of ephrine molecules is well known in embry-
onic tissue, their expressions/functions in adult remain unclear.
Aim: The aim of the present work is to characterize the cardiac phenotype
of two-months old ephrin-B1 knockout mice.
Results: Western-blot analysis demonstrated specific expression of ephrin-
B1 in total heart protein extracts from WT mice that was lost in KO mice.
Further IF studies demonstrated broad expression of ephrin-B1 protein
throughout all heart compartments (right ventricle, septum, left ventricle) with
different cellular localizations (cardiomyocytes and micro/macrocirculation).
HE stained-paraffin-embedded heart sections from KO mice revealed loss of
organized cardiac tissue characterized by the presence of wavy cardiomyo-
cytes in the myocardium from septum and right/left ventricles. Modification of
cardiomyocytes’ morphology correlates with a loss of their apparent lateral
junctions and a significant reduction in cytoskeleton proteins (α-actinin/β-
actin levels), consistent with a reduced size of the mycoytes. Ultrastructural
analysis (electronic microscopy) revealed significant loss of electronic density
of Z-disks and a highly packed intercalated disk (ID) with no modifications in
the ID space, probably as a consequence of myocytes’ lateral junction’s loss.
Functional analysis of KO-mice with echocardiography revealed a significant
increase in systolic and diastolic diameters of the left ventricle. Consistent
with disruption of myocardial architecture, electrocardiograms demonstrated a
first degree AV block together with a significant reduction of heart frequency.
Conclusion: This is the first report providing evidence for the presence of
ephrin molecules in the adult heart tissue. This study using ephrin-B1 KO
mouse identified ephrin-B1 as a new ultrastructural protein of the cardiomyo-
cyte whose deletion leads to a dilated cardiomyopathy.
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Background: Recent studies using healthy animals have demonstrated car-
dioprotective effects of erythropoietin (EPO) against ischemic-reperfusion injury
by up-regulation of the RISK pathway. Here, we sought to examine whether
EPO-induced cardioprotection and activation of cardioprotective signaling is
maintained in presence of type I diabetes mellitus or insulin resistance.
Methods: Isolated Langendorff-perfused hearts were obtained from 3
cohorts of Wistar rats: healthy adults; animals injected 4 weeks earlier with
streptozotocin (STZ) to induce diabetes and rats fed for 4 weeks with a high
fat diet (HFD) to induce insulin resistance. All hearts underwent 25min
ischemia, and within each cohort, were assigned to receive either 2h reperfu-
sion with no intervention or a single dose of EPO (1000 IU/kg) injected at the
onset of reperfusion.
Results: In hearts from healthy rats: i) EPO was cardioprotective: infarct
size was 14.36±0.60% vs 36.22±4.20% of the left ventricle (LV) in EPO-
treated vs untreated healthy rat hearts; p<0.05; ii) EPO-induced cardioprotec-
tion was associated with significant increases in phosphorylated forms of Akt,
ERK1/2 and their downstream target GSK-3β, at 30min of reperfusin. At
4 wks post-STZ injection, rats displayed: i) inhibition of EPO-induced cardio-
protection: infarct size was 32.05±2.38% vs 31.88±1.87% of the LV in EPO-
treated vs untreated diabetic rat hearts; ii) no up-regulation of PI3K/Akt,
ERK1/2 and GSK-3β signaling in response to EPO. In contrast, at 4 weeks
post-HFD, rats showed: i) cardioprotective effect of EPO: infarct size was
18.66±1.99% vs 34.62±3.41% of the LV in EPO-treated vs untreated HFD rat
hearts; p<0.05; ii) up-regulation in PI3K/Akt, ERK1/2 and GSK-3β signaling
in response to EPO, at 30min of reperfusion.
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 Mean age
(years)
Gender % 
of male
Abnormal 
ECG
%
Cardiac 
hypertrophy 
%
LW 
point 
(bpm)
HV 
interval 
(ms)
Val30Met 
n=13 42.5 53 47 40 128±3 59
Other 
mutations 
n=55
55.7 71 46 72 151±3 66
p 0.0001 0.04 NS 0.0002 <0.0001 0.002
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